Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John H Krege

Showing results (1-10 of 67) with videos related to

Pageof 7
Sort By:
Journal of Bone and Mineral Metabolism|January 7, 2010
First fractures among postmenopausal women with osteoporosisAngelina Sontag, John H Krege
Current Medical Research and Opinion|November 14, 2009
Benefits and risks of raloxifene by vertebral fracture statusAngelina Sontag, Xiaohai Wan, John H Krege
The New England Journal of Medicine|August 13, 2005
Teriparatide, osteoporosis, calcium, and vitamin DJohn H Krege, David W Donley, Robert Marcus
The Journal of Clinical Endocrinology and Metabolism|October 4, 2007
Response to teriparatide in patients with baseline 25-hydroxyvitamin D insufficiency or sufficiencyBess Dawson-Hughes, Peiqi Chen, John H Krege
The New England Journal of Medicine|July 23, 2025
Lepodisiran - A Long-Duration Small Interfering RNA Targeting Lipoprotein(a). ReplySteven E Nissen, Ann Marie Navar, John H Krege
Bone|June 1, 2005
Prognostic utility of a semiquantitative spinal deformity indexGerald G Crans, Harry K Genant, John H Krege
Bone|March 20, 2012
Changes in vitamin D metabolites during teriparatide treatmentFelicia Cosman, Bess Dawson-Hughes, Xiaohai Wan, et al.
Current Medical Research and Opinion|July 27, 2011
Long-term raloxifene for postmenopausal osteoporosisRobert R Recker, Bruce H Mitlak, Xiao Ni, et al.
Bone|December 21, 2010
PINP as an aid for monitoring patients treated with teriparatideMika Tsujimoto, Peiqi Chen, Akimitsu Miyauchi, et al.
Current Medical Research and Opinion|October 7, 2006
Comments on Initial experience with teriparatide in the United StatesKristine D Harper, John H Krege, Robert Marcus, et al.
Pageof 7

Showing results (1-10 of 67) with videos related to

Sort By:
Pageof 7
Journal of Bone and Mineral Metabolism|January 7, 2010
First fractures among postmenopausal women with osteoporosisAngelina Sontag, John H Krege
Current Medical Research and Opinion|November 14, 2009
Benefits and risks of raloxifene by vertebral fracture statusAngelina Sontag, Xiaohai Wan, John H Krege
The New England Journal of Medicine|August 13, 2005
Teriparatide, osteoporosis, calcium, and vitamin DJohn H Krege, David W Donley, Robert Marcus
The Journal of Clinical Endocrinology and Metabolism|October 4, 2007
Response to teriparatide in patients with baseline 25-hydroxyvitamin D insufficiency or sufficiencyBess Dawson-Hughes, Peiqi Chen, John H Krege
The New England Journal of Medicine|July 23, 2025
Lepodisiran - A Long-Duration Small Interfering RNA Targeting Lipoprotein(a). ReplySteven E Nissen, Ann Marie Navar, John H Krege
Bone|June 1, 2005
Prognostic utility of a semiquantitative spinal deformity indexGerald G Crans, Harry K Genant, John H Krege
Bone|March 20, 2012
Changes in vitamin D metabolites during teriparatide treatmentFelicia Cosman, Bess Dawson-Hughes, Xiaohai Wan, et al.
Current Medical Research and Opinion|July 27, 2011
Long-term raloxifene for postmenopausal osteoporosisRobert R Recker, Bruce H Mitlak, Xiao Ni, et al.
Bone|December 21, 2010
PINP as an aid for monitoring patients treated with teriparatideMika Tsujimoto, Peiqi Chen, Akimitsu Miyauchi, et al.
Current Medical Research and Opinion|October 7, 2006
Comments on Initial experience with teriparatide in the United StatesKristine D Harper, John H Krege, Robert Marcus, et al.
Pageof 7